In outpatient primary care clinics and emergency departments, standard 12-lead electrocardiograms (ECGs) are routinely recorded to check for rhythm disturbances or acute ischemia. Although ECGs are widely available, subtle patterns in their signals can be difficult to interpret by eye. A machine-learning model may flag patterns associated with valve disease, but cannot replace confirmatory imaging.

On September 25, 2026, the US Food and Drug Administration granted 510(k) clearance to Tempus AI for Tempus ECG-MR, software designed to flag signs associated with moderate or severe mitral regurgitation on resting 12-lead ECGs for eligible at-risk adults aged 65 and older. Its authorized Predetermined Change Control Plan (PCCP) sets out certain model changes that can be made without a separate 510(k) submission. Clinical and commercial value still depends on responsible follow-up.

In this deep dive

  • Why this matters now: The silent epidemiology of undiagnosed mitral regurgitation
  • What actually happened: Deconstructing the 510(k) clearance and PCCP authorization
  • The obvious read versus the deeper signal
  • The Evidence Ladder: Electrophysiological signatures to automated echo triage
  • Cardiovascular AI diagnostic taxonomy: ECG-AI vs Point-of-Care Ultrasound vs Cardiac CT
  • Health system economics: Driving transcatheter valve (TEER) procedural volume
  • The HealthTech Investor's Signal: Multimodal platform moats and model change control
  • The Counter-Thesis: Echo lab capacity bottlenecks and false-positive overutilization
  • Forward Intelligence: Four observable clinical and operational milestones
  • The Bottom Line for Hospital C-Suites and HealthTech Operators

Why This Matters Now: The Undiagnosed Valvular Disease Gap

Mitral regurgitation (MR) affects over 10% of individuals over age 75, making it the most prevalent heart valve condition in the aging population. Left untreated, chronic severe MR causes progressive left atrial enlargement, atrial fibrillation, irreversible left ventricular remodeling, and heart failure. However, because early-stage MR is frequently asymptomatic or presents with non-specific fatigue, valve disease can remain unrecognized until symptoms prompt evaluation.

Standard diagnostic evaluation requires a transthoracic echocardiogram (TTE), whose cost and availability vary by setting. Applied to eligible patients already receiving ECGs, ECG-MR can provide a flag that clinicians may use when deciding whether confirmatory imaging is warranted.

What Actually Happened: FDA Clearance & PCCP Scope

The FDA cleared Tempus ECG-MR under 510(k) K254297, regulation 21 CFR 870.2380. It flags ECG patterns associated with moderate or severe mitral regurgitation; echocardiography remains the diagnostic test. Key regulatory and technical details include:

  • Intended Population: Non-ambulatory resting 12-lead ECGs recorded at healthcare facilities from patients aged 65 or older who meet the device’s specified cardiovascular risk and exclusion criteria.
  • Clinical Output: Binary flag alerting the clinician to a heightened probability of moderate or severe mitral regurgitation to prompt comprehensive echocardiographic evaluation.
  • Predetermined Change Control Plan (PCCP): The FDA authorized an official PCCP, allowing Tempus to iteratively retrain and update its machine learning models within pre-specified performance boundaries without filing redundant 510(k) submissions.
  • Portfolio Expansion: ECG-MR adds to Tempus AI's FDA-cleared ECG portfolio, complementing existing algorithms for arrhythmia, reduced left ventricular ejection fraction, and pulmonary hypertension.

The Obvious Read Versus the Deeper Signal

The surface takeaway is that Tempus added another AI feature to its cardiology suite. The deeper strategic question is whether an ECG flag reliably leads to appropriate confirmatory imaging and specialist care. Some patients with confirmed disease may eventually be evaluated for transcatheter edge-to-edge repair (TEER), but neither a procedure nor an avoided admission follows automatically from a positive flag.

A clinician reviews ECG and echocardiography screens in a cardiology clinic.
A clinician reviews ECG and echocardiography screens in a cardiology clinic.

🔒 HEALTHTECH SIGNAL PLUS · EXCLUSIVE SUBSCRIBER INTELLIGENCE